Recently Approved

April 2009
Pharmaceutical Representative;Apr2009, Vol. 39 Issue 4, p10
The article provides information on several therapeutics which were approved by the Food & Drug Administration (FDA) in the U.S. An overview of recently approved medications for various diseases is provided which includes Prezista from Tibotec Therapeutics, Gelnique from Watson Pharmaceuticals, and Symbicort from AstraZeneca.


Related Articles

  • Pipeline preview.  // Formulary;Sep2008, Vol. 43 Issue 9, p316 

    The article reports developments on various drugs seeking for approval from the U.S. Food and Drug Administration (FDA). Zipsor and Xanodyne are asked for immediate-release for the treatment of mild-to-moderate acute pain. Tocilizumab, a new drug introduced for the reduction of signs and...

  • OBSERVATIONS. Formanek Jr., Raymond // FDA Consumer;Mar/Apr2006, Vol. 40 Issue 2, p2 

    The article deals with the distinct approaches developed by the U.S. Food and Drug Administration intended to make important treatments for serious diseases available more rapidly to those who desperately need them. The approaches include fast track designation of drugs, accelerated approval and...

  • Pregabalin provides relief from fibromyalgia-related pain.  // Formulary;Jun2007, Vol. 42 Issue 6, p395 

    The article discusses the relief provided by pregabalin for fibromyalgia-related pain in the U.S. According to the results of a 14-week study, patients with pain related to fibromyalgia syndrome (FMS) can experience a greater or equal to 50% reduction in pain if they are treated with pregabalin....

  • News and Views. Laffman, Elise // Clinical Pharmacology & Therapeutics;Jan2008, Vol. 83 Issue 1, p8 

    The article presents news briefs related to clinical pharmacology and therapeutics. The U.S. Food and Drug Administration (FDA) has proposed a change in existing black box warnings for antidepressant drugs to warn of an increased risk of suicidality in young adults from 18 to 24 years old. A new...

  • CHELSEA BEGINS PATIENT DOSING IN DROXIDOPA PHASE III.  // Biotech Business;Oct2008, Vol. 21 Issue 10, p4 

    The article reports that Chelsea Therapeutics International, Ltd. has started the second of two pivotal Phase III trials on patient dosing determined to show the potency and support the approval of Droxidopa in neurogenic orthostatic hypotension (NOH). This study was awarded a Special Protocol...

  • Regulating the Generic Drug Process. Wood, Daniel N.; Gregory, Christopher W. // Applied Clinical Trials;Sep2009, Vol. 18 Issue 9, p34 

    The article focuses on the guidance documents for the design and conduct of international bioequivalence trials which are helpful for planning and implementing them to support approval of generic drug products. However, it mentions that the documents are not able to provide comprehensive...

  • New drug update 2003: Part 2. Boothby, Lisa A.; Doering, Paul L. // Drug Topics;3/8/2004, Vol. 148 Issue 5, p82 

    Reviews the new molecular entities approved by the Food and Drug Administration in 2003. Gemifloxacin mesylate; Ibandronate Sodium; Memantine HCl; Miglustat.

  • Looking Back, FDA Approvals Continue To Trend Down In '06. Lorenzo, Aaron // BioWorld Today;3/12/2007, Vol. 18 Issue 48, p3 

    The article offers information on the product approvals of the U.S. Food and Drug Administration (FDA) in 2006. According to a released document, the FDA approved 32 molecular entities in 2006. Majority of the products were cleared by the Center for Drug Evaluation and Research (CDER). Among...

  • FDA OKs new HIV drug. Roehr, Bob // Bay Area Reporter;6/29/2006, Vol. 36 Issue 26, p3 

    The article reports on the approval made by the Food and Drug Administration on the sale of Prezista on June 23, 2006, as part of combination therapy treatment-experienced adults with HIV in the U.S. According to Paul Dalton of San Francisco-based Project Inform, evidence suggests that this is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics